AST-1601

N/A

Report date: 2023/03/05 16:38:27
NME

Base Information

Drug NameAST-1601
Drug Alias NameAST-1601
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionUpdating
TargetsUpdating
Therapy Area/IndicationsLeukemia, Myeloid, Chronic-Phase
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesTaizhou Ansdal Biotechnology Co Ltd
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesTaizhou Ansdal Biotechnology Co Ltd
Inactive CompaniesN/A
Active IndicationsLeukemia, Myeloid, Chronic-Phase
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A